ArticleGeneral hospital psychiatry
Melatonin prescribing characteristics and delirium outcomes: A health system database-based study.
Article in General hospital psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThere is heterogeneity in melatonin use for the prevention and treatment of delirium. The optimal dosing and timing of melatonin for these indications are unknown. This study's objectives were to describe melatonin prescribing for hospitalized inpatients in a large healthcare system and to evaluate associations between melatonin prescribing, rates of delirium, and hospital length of stay (LOS)
methodsA centralized health data repository was queried for all inpatients ages 18 and above who had received at least one dose of melatonin from October 2019 to September 2024. General linear models were used in analyses, with average daily dose of melatonin and average time of melatonin administration serving as exposure variables, and rates of delirium and LOS serving as outcomes. Covariates included demographic variables, antipsychotic/benzodiazepine use, and comorbidities
resultsA total of 83,760 patients were included in the cohort. Higher average daily doses of melatonin were associated with lower odds of hospital delirium (OR 0.92, p < 0.001), but melatonin administered from 5 to 8 pm was associated with higher odds of delirium (OR 1.55, p < 0.001). In predicting LOS, there was a decrease of 0.86 days in LOS with every milligram increase in average daily dose of melatonin (95% CI: -0.97 to -0.75, p < 0.001); however, there was an increase of 5.26 days in LOS when melatonin was administered from 5 to 8 pm (95% CI: 4.80 to 5.73, p < 0.001)
conclusionHigher average daily doses of melatonin and melatonin dosed outside the 5-8 pm timeframe were associated with lower odds of delirium and shorter LOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.